Five year outcomes of care for prostate cancer in New South Wales

前列腺癌是澳大利亚男性中最常见的癌症，仅次于非黑色素细胞皮肤癌。每年有10,000多名男性被诊断出患有前列腺癌，超过2,500人死于前列腺癌。虽然使用前列腺特异性抗原检测早期发现前列腺癌的问题仍然存在争议，但患者、临床医生和健康规划者对治疗后的长期生活质量仍然非常感兴趣。前列腺癌结果研究是一个已经确立的研究项目，成立于2000年，目的是记录2000名前列腺癌患者到确诊后五年的生活质量结果。退伍军人事务部在2000至2005年间资助了这项研究，以建立队列，从临床医生那里收集护理信息，并从参与者那里收集到诊断后3年的生活质量信息。我们现在正在寻求资金，以完成每个幸存参与者在确诊后五年的生活质量随访。我们还将评估前列腺癌的复发率至五年，并寻求支持，以便能够与死亡证明信息联系起来，以确定每个研究对象的生命状态，并开始分析五年生存率。五年的生活质量信息将是这部分研究的主要终点。对三年数据的初步分析显示，与尿路和性功能相关的结果持续改善。我们希望确定这些改善是否会持续五年，以及当时前列腺癌患者和非前列腺癌患者(对照组)之间的差异程度，我们也在研究前列腺癌患者。这些信息将在帮助男性在被诊断为前列腺癌时做出治疗选择的决定方面独一无二地有用。

Prostate cancer is the most common cancer in Australian males after non-melanocytic skin cancer. Each year more than 10,000 men are diagnosed with prostate cancer, and over 2,500 die from it. While the issue of early detection of prostate cancer through the use of Prostate Specific Antigen test continues to raise debate, the longer term quality of life outcomes after treatment for this disease remain of great interest to patients, clinicians and health planners. The Prostate Cancer Outcomes Study is an already established research project that was established in 2000 with the aim of documenting the quality of life outcomes of 2000 men with prostate cancer to five years after diagnosis. The Department of Veterans Affairs funded the study between 2000 and 2005, to establish the cohort, collect patterns of care information from clinicians and quality of life information from participants to 3 years post diagnosis. We are now seeking funds to complete the quality of life follow up for each surviving participant at five years after diagnosis. We also will assess rate of recurrence of prostate cancer to five years and seek support to be able to undertake linkage with death certificate information to determine the vital status of each study subject and begin analysis of five-year survival rates. Five-year quality of life information will be the main endpoint for this part of the study. Initial analysis of the three-year data showed a continued improvement in outcomes related to urinary and sexual function. We wish to determine whether these improvements continue to five years and the extent of the difference, at that time, between men with prostate cancer and men without prostate cancer (controls), whom we are also studying. This information will be uniquely useful in helping men make decisions about treatment options when diagnosed with prostate cancer.